Sglt2i and GLP-1RA improved CV morbidity and mortality in patients with T2D compared to DPP-4i in combination. The results of this study can serve as a basis for the selection of an optimal antidiabetic add-on to reduce CV morbidity and mortality in patients with T2D in clinical practice. Additional material This content has been made available by the author(s). It has not been verified by BMJ Publishing Group Limited (BMJ) and may not have been evaluated by experts. All opinions or recommendations discussed are exclusively those of the author and are not supported by BMJ. BMJ disclaims all liability and liability arising from reliance on the content.